Skip Navigation

DRUG RECORD

 

ETODOLAC

OVERVIEW
Etodolac

 

Introduction
Etodolac is a nonsteroidal antiinflammatory drug (NSAID) that is available by prescription only and is used long term for therapy of chronic arthritis and short term for acute pain.  Etodolac has been linked to rare instances of clinically apparent drug induced liver disease.

Background
Etodolac (e toe' doe lak) belongs to the acetic acid derivative class of NSAIDs similar to diclofenac, sulindac, ketorolac and indomethacin.  Like other NSAIDs, etodolac is a potent cyclo-oxygenase (Cox-1 and -2) inhibitor which blocks the formation of prostaglandins that are important in pain and inflammatory pathways.  It has analgesic as well as antipyretic and antiinflammatory activity.  Etodolac was approved in the United States in 1991 and is available by prescription only.  Currently more than 3 million prescriptions are filled yearly.  Current indications include treatment of osteoarthritis and rheumatoid arthritis and for short term treatment of acute pain.  Etodolac is available as capsules or tablets in doses of 200, 300, 400 and 500 mg in both generic and trade formulations.  Etodolac is sold under the trade name of Lodine.  Extended release formulations of 400, 500 and 600 mg are also available for once or twice daily dosing.  The recommended dose is 400 to 1200 mg in 2 to 4 divided doses daily, based upon response and tolerance.  Like other NSAIDs, etodolac is generally well tolerated, but side effects can include headache, dizziness, somnolence, dyspepsia, nausea, abdominal discomfort, heartburn, diarrhea, peripheral edema, pruritus and hypersensitivity reactions.

Hepatotoxicity
Prospective studies show that 1% to 2% of patients taking etodolac experience at least transient serum aminotransferase elevations.  These may resolve even with drug continuation.  Marked aminotransferase elevations (>3 fold elevated) occur in <1% of patients.  Clinically apparent liver injury with jaundice from etodolac is rare and only individual case reports have been published.  The latency to onset ranged a few days to several months and the pattern of enzyme elevations has been described as cholestatic, hepatocellular and mixed.  A case of fatal hepatocellular injury has been described.  Nevertheless, hepatic injury from etodolac must be very rare.  Etodolac is not mentioned in large case series on drug induced liver injury or acute liver failure.  Interestingly, etodolac causes a false positive reaction on dipstick testing for bilirubin in urine.

Mechanism of Injury
The mechanism of etodolac hepatotoxicity is not known, but likely to be due to an idiosyncratic reaction to an intermediate of its metabolism.  Etodolac is extensively metabolized by the liver.

Outcome and Management
Severity ranges from asymptomatic elevations in serum aminotransferase levels, to symptomatic hepatitis with or without jaundice.  A single fatal case has been described.  Patients with etodolac induced clinically apparent liver injury should avoid other acetic acid derivatives such as sulindac, diclofenac, ketorolac, tolmetin and indomethacin.

 

Drug Class:  Nonsteroidal Antiinflammatory Drugs

 

Top of page

 

CASE REPORTS
Etodolac

 

Case 1.  Acute hepatitis attributed to etodolac.
[Modified from a case in the database of the Drug-Induced Liver Injury Network.]

 

A 55 old year woman developed anorexia followed by skin rash 7 months after starting etodolac (400 mg twice daily) for osteoarthritis.  She stopped the etodolac, but went on to develop dark urine and jaundice.  She had no history of liver disease, alcohol abuse, risk factors for viral hepatitis or drug allergieis.  Her other medical conditions included hypothyroidism for which she took levothyroxine and reactive airway disease for which she had taken montelukast daily for several years.  She also took multivitamins, but denied exposure to other over-the-counter or herbal products.  On examination, she had an erythematous rash over the thorax, but no fever or lymphadenopathy, and no signs of chronic liver disease.  Laboratory tests showed total serum bilirubin of 4.0 mg/dL, ALT 661 U/L, AST 501 U/L, alkaline phosphatase 128 U/L and albumin 4.0 g/dL.  Tests for hepatitis A, B, C (including HCV RNA) and E were negative as were ANA and SMA.  An abdominal ultrasound showed gallstones, but no evidence of biliary obstruction.  She was monitored as an outpatient and improved rapidly.  Her symptoms resolved within one month and all liver tests were normal within two months of the initial presentation (Table).  She did not restart etodolac.


Key Points

Medication: Etodolac
Pattern: Hepatocellular (R=19.3)
Severity: 2+ (jaundiced but not hospitalized)
Latency: 7 months
Recovery: 7 weeks
Other medications: Montelukast, levothyroxine, multivitamins

Laboratory Values

Time After Starting Time After Stopping ALT (U/L) Alk P (U/L) Bilirubin (mg/dL) Other
7 months
14 days
661
128
4.0
Ultrasound normal
 
21 days
327
102
2.7
 
 
30 days
114
87
1.6
Asymptomatic
8 months
37 days
56
66
1.3
 
44 days
35
58
1.4
 
51 days
27
58
0.8
10 months
3 months
16
54
0.8
18 months
12 months
22
46
0.8
Normal Values
<65
<136
<1.2

Comment

This woman developed a mild, but clinically apparent acute hepatitis 7 months after starting daily etodolac therapy for osteoarthritis.  Immunoallergic features were present (rash), but not prominent (not eosinophil counts were available).  Other causes of acute hepatitis were excluded.  Montelukast can cause acute liver injury, but she had been on this medication for several years.  Rechallenge with motelukast with careful monitoring would have been appropriate.

 

Top of page

 

 

Clinical cases of drug-induced liver injury that have been submitted to LiverTox ("Submit a Case Report") are available for review.  Most of these reference cases are from

the Drug-Induced Liver Injury Network, but others are from users of LiverTox who have submitted data from an actual clinical case.  All cases have been reviewed and cleared

of personal identifiers and a brief comment added by the LiverTox editors.  Click on the following link to view the submitted case reports that have been made publically available.


Submitted Cases on Etodolac

 

Top of page


PRODUCT INFORMATION
Etodolac

 

REPRESENTATIVE TRADE NAMES
Etodolac – Generic, Lodine®


DRUG CLASS
Nonsteroidal Antiinflammatory Drugs


COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Etodolac 41340-25-4 C17-H21-N-O3 Etodolac chemical structure

Top of page


REFERENCES
Etodolac

 

References updated: 25 March 2015

  1. Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-553.  (Expert review of hepatotoxicity published in 1999; mentions that etodolac is associated with a low rate of serum aminotransferase elevations and has been implicated in a few cases of acute liver injury with jaunidce).

  2. Lewis JH, Stine JG.   Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam:  Elsevier, 2013, pp. 369-401.  (Review of hepatotoxicity of NSAIDs; mentions that ALT elevations occur in <1% of patients on etodolac and discusses a case report of acute liver failure [Mabee et al 1995]).

  3. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents: pharmacotherapy of gout. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 959-1004.  (Textbook of pharmacology and therapeutics).

  4. Karbowski A. A global safety evaluation of etodolac. Clin Rheumatol 1989; 8 (Suppl 1): 73-9. PubMed Citation   (Review of the literature and data on file with sponsor on safety of etodolac: liver test abnormalities occurred in 1-2% of treated patients, but none withdrew because of laboratory abnormalities. In clinical practice studies on 543 patients there were no reports of hepatitis or liver function test abnormalities).

  5. Zimmerman HJ. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroid drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 1990; 10: 322-8. PubMed Citation  (Extensive review article on liver injury due to NSAIDs; mentions that etodolac has “led to little or no hepatic injury”).

  6. Schattenkirchner M. An update safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990; 10: 56-65. PubMed Citation  (In clinical trials, 31 of 3,302 [0.9%] patients on etodolac stopped treatment because of elevated liver enzymes [ALT, AST or Alk P] or bilirubin, compared to 0.4% of placebo- and 4% of aspirin-recipients).

  7. Serni U. Global safety of etodolac: reports from worldwide postmarketing surveillance studies. Rheumatol Int 1990; 10(Suppl): 23-7. PubMed Citation   (Summary of 4 post-marketing studies of safety of etodolac from Europe in over 8000 patients: in a French study of 1269 patients, 2 cases of hepatoxicity were reported, one with jaundice only and one with cholestatic hepatitis).

  8. Benhamou CL. Large-scale open trials with etodolac(Lodine) in France: an assessment of safety. Rheumatol Int 1990; 10 Suppl: 29-34. PubMed Citation   (Analysis of safety in 4997 patients in randomized clinical trials of 30-day course of etodolac in rheumatoid arthritis and osteoarthritis, found one patient with marked ALT elevations at 15 days and one case of cholestatic hepatitis, both resolving; in 51,355 patients in post-marketing surveillance, only 2 hepatic adverse reactions were reported, but no details given).

  9. Schattenkirchner M. Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. Curr Med Res Opin 1991; 12: 497-50.  PubMed Citation (60 patients given etodolac [200 mg twice daily] or piroxicam [20 mg once daily] for 12 weeks with blood chemistries done at start and stop of therapy; “There were no clinically significant changes in laboratory parameters in either treatment group”).

  10. Etodolac. Medical Letter 1991; 33: 79-80. PubMed Citation  (Short review of etodolac indicating that it is as effective as other NSAIDs but unlikely to be more safe; also mentions that drug-associated hepatic dysfunction has been reported).

  11. Latrive JP, Combaux D, Crepin P, Brbara JC. Acute hepatitis associated with etodolac therapy. Therapie 1992; 47: 82. PubMed Citation  (32 year old woman with anklyosing spondylitis developed jaundice 5 days after starting etodolac [bilirubin 6.3 mg/dL, ALT 8 times and Alk P 2.7 times ULN] with complete resolution in 2 months).

  12. Schattenkirchner M. The safety profile of sustained-release etodolac. Rheumatol Int 1993; 13(Suppl 2): S31-5.  PubMed Citation  (Among 539 patients with osteoarthritis or rheumatoid arthritis given once daily sustained release etodolac in 4 open-label studies for up to 1 year; “most laboratory abnormalities were transient and did not affect the patient’s health status.” 6 patients withdrew because of laboratory abnormalities, all of which resolved except for one patient with pre-existing liver test abnormalities. No mention of hepatitis or jaundice).

  13. García Rodríguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154: 311-6. PubMed Citation  (Population based study of 625,307 UK subjects who received at least one prescription for one of 12 NSAIDs [etodolac not mentioned], of whom 35 subsequently had liver injury: 12 only liver tests abnormal, 23 acute symptomatic injury for and overall incidence of 1 per 100,000 prescriptions or 4 per 100,000 users).

  14. Schnitzer TJ, Ballard IM, Constantine G, McDonald P. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Clin Therapeut 1995; 17: 602-12. PubMed Citation  (In a prospective controlled trial, mild ALT elevations occurred in 3 of 89 nabumetone-, none of 90 etodac-, and 2 of 90 placebo-treated patients; no mention of outcome or symptoms).

  15. Mabee CL, Mabee SW, Baker PB, Kirkpatrick RB, Levine EJ. Fulminant hepatic failure associated with etodolac use. Am J Gastroenterol 1995; 90: 660-2. PubMed Citation  (67-year old woman developed an acute hepatitis 4 months after starting etodolac for osteoarthritis [bilirubin 11.8 mg/dL, ALT 1554 U/L, Alk P 193 U/L, protime 21.4 sec], progressing to hepatic failure and death within 3 weeks of onset).

  16. Neustadt DH. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl 1997; 47: 17-22. PubMed Citation  (Randomized trial of 2 doses of etodolac vs ibuprofen in 1446 patients with rheumatoid arthritis treated for up to 3 years; similar efficacy; “Changes in hepatic and renal function were similar across treatment groups” and “rates… were low”, but higher dose of etodolac had higher rate of Alk P elevations; all resolved with stopping).

  17. Cunha PD, Lord RS, Johnson ST, Wilker PR, Aster RH, Bougie DW. Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug. Transfusion 2000; 40: 663-8. PubMed Citation  (41 year old woman developed jaundice after intermittent use of etodolac [total bilirubin 17.6 mg/dL, direct 6.8 mg/dL, AST 284 U/L, Alk P 125 U/L, protime 19.8 sec] with hemolytic anemia [hematocrit 18%, positive direct Coombs test], resolving within 2 months but with recurrence of hemolysis on restarting etodolac).

  18. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 373-80. PubMed Citation (NSAIDs are the most commonly used drugs in the U.S. and account for a large proportion of cases of hepatic injury, but the frequency is quite rare. Among 7 population-based studies, hospitalization occurred in 22.4 per 100,000 patient-years [rate ratio 1.5], and ~1 death per 100,000 patient-years was due to liver injury; rate of injury did not increase with age or vary by gender; in case-controlled studies, higher odds ratios were found with sulindac, indomethacin, piroxicam and diclofenac; analysis dealt largely with commonly used NSAIDs and did not mention etodolac).

  19. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489-98. PubMed Citation  (Review of randomized clinical trials of NSAIDS for frequency of adverse events; ALT above 3 times ULN in 0.43% of ibuprofen, 0.43% naproxen, 0.42% celecoxib, 1.8% rofecoxib, 3.55% diclofenac and 0.29% of placebo recipients, rare liver-related serious adverse effects or deaths with any; dealt largely with commonly used NSAIDs and did not mention etodolac).

  20. Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-101. PubMed Citation  (Survey of all cases of drug induced liver injury with fatal outcome from Swedish Adverse Drug Reporting system from 1966-2002: among 103 cases, none were attributed to etodolac).

  21. Griffin A. Case of the month. Chronic hepatitis. JAAPA 2006; 19: 70. PubMed Citation  (54 year old man taking etodolac for low back pain was found to have 3+ bilirubin in urine by dipstick, but serum ALT, AST and bilirubin were normal; the reaction because negative 10 days after stopping and was positive again 2 weeks after restarting, due to false-positive reaction of the diazo reagent).

  22. Lapeyre-Mestre M, de Castro AM, Bareille MP, Del Pozo JG, Requejo AA, Arias LM, et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006; 20:391-5. PubMed Citation  (Analysis of reports of liver injury from NSAIDs from France and Spain from 1982-2001; etodolac is not listed in tables of adverse event reports from NSAIDs).

  23. Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, et al. Use of cyclo-oxygenase 2 inhibitors(COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006; 15 :861-72. PubMed Citation   (Survey of NSAID use in UK and USA indicates ibuprofen, naproxen and diclofenac are the most commonly used; etodolac was not among the top 10 agents used).

  24. Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs 2008; 26: 139-49. PubMed Citation  (Use of high doses of a R-enanomer of etodolac [1.2 to 4.8 g/day] was associated with decrease in lymphocyte counts in patients with chronic lymphocytic leukemia; the activity was separate from Cox inhibition and not shared by other NSAIDs; in this phase I trial, ALT elevations occurred in 11 of 45 patients [26%], were unrelated to dose, and led to drug withdrawals in 3 [7%]; no mention of hepatitis).

  25. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. PubMed Citation  (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, NSAIDs were implicated as a sole agent in 8 cases [4 diclofenac, 2 celecoxib, 1 meloxicam and 1 oxaprozin] and as one of several agents in 3 cases [1 diclofenac, 1 celecoxib, 1 ibuprofen]; no cases were attributed to etodolac).

  26. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76. PubMed Citation  (Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, of which 7 were due to NSAIDs, including 4 attributed to bromfenac, 2 to diclofenac and 1 to etodolac).

  27. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651-61.  PubMed Citation  (Review of estimated frequency of drug induced liver injury due to NSAIDs from large published epidemiological studies; mentions that etodolac has been associated with various hepatic reactions).

  28. Mehta P, Lukacs M, Abraham SM. Normal in the blood, abnormal in the urine. QJM 2012; 105: 1001-2. PubMed Citation  (67 year old woman with rheumatoid arthritis on etodolac had persistent positive urine dipstick reaction for bilirubin despite normal serum bilirubin and liver tests; false positive reaction was due to etodolac).

  29. Sampaziotis F, Brais RJ, Griffiths WJ. A case of acute liver failure due to etodolac. Br J Clin Pharmacol 2013; 75: 1156-7. PubMed Citation  (73 year old woman developed jaundice 6 months after starting etodolac [bilirubin 30.7 mg/dL, ALT 1400 U/L, Alk P 274 U/L, protime 16.7 seconds], developing hepatic encephalopathy, but then recoverying spontaneously within 3 months of stopping).

Top of page


OTHER REFERENCE LINKS
Etodolac
  1. PubMed logoRecent References on Etodolac

  2. Clinical Trials logoTrials on Etodolac

Top of page